Otsuka Pharmaceutical

Abilify (aripiprazole) is an atypical antipsychotic from Otsuka. Rather than fully blocking dopamine signals, it partially stimulates dopamine D2 receptors, steadying overactive circuits. It is used in schizophrenia and bipolar I disorder, and as add-on therapy in major depressive disorder.

Many symptoms of schizophrenia and mania are linked to overactive dopamine signalling. Aripiprazole attaches to dopamine D2 receptors but only partial

Rexulti (brexpiprazole) is an atypical antipsychotic from Otsuka that modulates dopamine and serotonin receptors. It is used in schizophrenia, as an add-on to antidepressants in major depressive disorder, and for agitation associated with dementia due to Alzheimer's disease.

Brexpiprazole belongs to a class of medicines that adjust how brain circuits respond to the chemical messengers dopamine and serotonin. It partially s